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ing an erythropoiesis-stimulating therapy (EST). Patients were
included in this analysis if they were >=65 years old and received
therapy between October 2005 and October 2006. Patient
demographics, comorbid conditions, baseline hemoglobin, CKD
status, EST dose, and frequency of administration were collected.
Drug cost was based on average weekly dose and September
2006 wholesale acquisition cost (EPO $12.17/1000 Units; DARB
$4.446/mcg). RESULTS: 862 patient charts were reviewed; 556
patients met eligibility criteria (EPO: 351; DARB: 205). Patient
demographics, comorbid conditions, baseline hemoglobin, and
CKD status were similar between groups. Weekly and extended
(>= every two weeks [>= Q2W]) dosing patterns were seen in
both groups (EPO: QW, 39%; >= Q2W, 61%; DARB: QW, 8%;
>= Q2W, 92%). The average weekly dose over the course of the
study (EPO: 10,719 units; DARB: 48 mcg) corresponded to a
dose ratio of 223 : 1 (Units EPO: mcg DARB) and weekly costs
of $130 for EPO and $213 for DARB. CONCLUSION: The
doses and 39% lower drug cost in the EPO group observed in
this study were similar to those published from earlier time
periods. The results reported here should be of assistance to clin-
icians and formulary decision makers in identifying current real-
world dosing and subsequent cost of treatment of these two
erythropoietic agents.
CS2
OUTCOMES ASSOCIATED WITH THE USE OF
THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES
WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE
APPROACH
Fang G1, Zuckerman IH1, Stuart B1, Brooks JM2
1University of Maryland, Baltimore, MD, USA, 2The University of Iowa,
Iowa City, IA, USA
OBJECTIVES: To study treatment outcomes (total cost, hospi-
talization, hospital stays and physician ofﬁce visits) associated
with thiazolidinedione (TZD) use among Medicare patients with
type II diabetes. METHODS: Medicare Current Beneﬁciary
Survey Cost and Use ﬁles 2000 and 2001 were used. Patient-year
approach was utilized. After applying inclusion and exclusion
criteria, patients’ sociodemographic and clinical characteristics
were characterized and compared across different treatment
groups. Instrumental variable (IV) methodology was applied
with TZD geographic area use rate as instrument and IV assump-
tions were validated. The results of IV method were compared
to that of standard ordinary least square (OLS) approach.
RESULTS: A total of 417 patients were included in the ﬁnal
analysis. More patients with actual TZD treatment had comor-
bidities >0 (69.8% vs. 56.4%, p < 0.05) and less were non-
white/black race (1% vs 7%, p < 0.05) than those without. The
TZD use rates were 17% and 29% for lower (<20%) and higher
TZD area use rate groups respectively (p < 0.01). Unadjusted
OLS models showed that actual TZD use was associated with
increased total annual cost (co-efﬁcient = 0.38, p < 0.01) and risk
of having more physician ofﬁce visits by 81%. Adjusted OLS
models showed that actual TZD use was still associated with
increased total annual cost (co-efﬁcient = 0.23, p < 0.05) and risk
of having more physician ofﬁce visits by 64% (p < 0.05). IV
approach demonstrated that higher TZD area use rate was not
associated with total annual cost, hospitalization and hospital
stays (p > 0.1). IV assumption for physician ofﬁce visits was vio-
lated as indicated by a signiﬁcant Wu-Hausman test. CON-
CLUSION: Increasing average TZD area treatment rate from
17% to 29% would not lead to increased total annual cost, hos-
pitalization and hospital stays among marginal patients in the
cohort of senior diabetic patients in this study. Future research
utilizing data with large sample size is suggested.
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OBJECTIVES: Both cost and quality are major concerns in the
U.S. health care system. The objective of this study is to identify
the relationship between cost and quality from the health care
consumers’ perspective. METHODS: Using the 2003 Medical
Expenditure Panel Survey (MEPS), a nationally representative
sample of 13,980 adults (age ≥ 18) with their overall self-rating
of health care quality (from 0 (worst health care possible) to 
10 (best health care possible)) were included in the study. Given
the heavily right-skewed distribution of the cost data, a general-
ized linear model with log-link function was employed to iden-
tify the relationship between health care quality rating and 
total health care expenditure, after controlling for individual
demographic covariates, comorbidity proﬁle (AHRQ comorbid-
ity software), and functional and activity limitations. All sta-
tistics were adjusted using the proper sampling weight from 
the MEPS. RESULTS: The average annual health care expendi-
tures ranged between $4000 and $6000 with the mean value
$4779 for all individuals rating their received health care quality
from 0 to 10. Individuals with higher ratings for their health 
care quality did not spend more compared to individuals with
lower ratings (p = 0.72). No non-monotonic relationship 
was identiﬁed either. As one expected, comorbidities and func-
tional and activity limitations were signiﬁcant predictors of the
annual health care expenditure. An individual-level ﬁxed-effect
model using the 2003–2004 panel of the MEPS revealed the same
relationship between health care quality rating and total health
care expenditure. CONCLUSION: This study adds to the liter-
ature of health care quality by providing additional empirical evi-
dence from the health care consumers’ perspective at the U.S.
national level. Health care quality improvement, in regards to
patient satisfaction, may not require additional health care
spending.
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OBJECTIVES: This study presents a methodology to estimate
type II diabetes prevalence, treatment and costs among the ∼178
million individuals in the U.S. with employer-sponsored insur-
ance (ESI). METHODS: Estimates were made from the 2005
MarketScan® Commercial and Medicare supplemental data-
bases, which include all health care claims for approximately 
20 million employees, dependents, and retirees with ESI. The
Sample Select Prevalence tool was used to identify patients with
Type II diabetes (ICD-9-CM = 250.x0 or 250.x2) and drug treat-
ment (insulin, sulfonylurea, or other oral antidiabetic drug),
summarize annual health care expenditures, and calculate preva-
lence rates. To project these rates to the national ESI population,
weights were developed using the Household Component of the
Medical Expenditure Panel Survey (MEPS). To construct the
weights, MEPS respondents were stratiﬁed using combinations
of demographic characteristics which account for substantial dif-
ferences in utilization and expenditures. RESULTS: In the 2005
MarketScan databases, 835,048 patients with diabetes (5320
